Actifed New

Hauptinformation

  • Handelsname:
  • Actifed New Sirup 15 mg;5 ml
  • Dosierung:
  • 15 mg;5 ml
  • Darreichungsform:
  • Sirup
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Actifed New Sirup 15 mg;5 ml
    Belgien
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • AFMPS - Agence Fédérale des Médicaments et des Produits de Santé - Belgium
  • Zulassungsnummer:
  • BE227893
  • Letzte Änderung:
  • 06-04-2018

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Version 26

Gebrauchsinformation: Information für Anwender

Actifed New 15 mg/ 5 ml Sirup

Dextromethorphanhydrobromid

Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme dieses

Arzneimittels beginnen, denn sie enthält wichtige Informationen.

Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals lesen.

Wenn Sie weitere Fragen haben, wenden Sie sich an Ihren Arzt oder Apotheker.

Dieses Arzneimittel wurde Ihnen persönlich verschrieben. Geben Sie es nicht an Dritte weiter. Es

kann anderen Menschen schaden, auch wenn diese die gleichen Beschwerden haben wie Sie.

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies gilt

auch für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind.

Siehe Abschnitt 4.

Was in dieser Packungsbeilage steht

1. Was ist Actifed New und wofür wird es angewendet?

2. Was sollten Sie vor der Einnahme von Actifed New beachten?

3. Wie ist Actifed New einzunehmen?

4. Welche Nebenwirkungen sind möglich?

5. Wie ist Actifed New aufzubewahren?

6. Inhalt der Packung und weitere Informationen

1. Was ist Actifed New und wofür wird es angewendet?

Actifed New ist ein Arzneimittel gegen Erkrankungen der oberen Atemwege. Es enthält

Dextromethorphan, einen Wirkstoff, der sich als Hustenstiller als wirksam erwiesen hat.

Dieser Sirup wird zur Behandlung von Beschwerden angewendet, die durch einen trockenen,

störenden Reizhusten verursacht werden.

2. Was sollten Sie vor der Einnahme von Actifed New beachten?

Actifed New darf nicht eingenommen werden,

wenn Sie allergisch gegen den Wirkstoff (Dextromethorphanhydrobromid) oder einen der in

Abschnitt 6. genannten sonstigen Bestandteile dieses Arzneimittels sind,

wenn Sie an einer Ateminsuffizienz leiden (wenn Sie beispielsweise an COPD oder Pneumonie

leiden oder während eines Asthmaanfalls oder einer Exazerbation).

wenn Sie an asthmatischem Husten leiden.

wenn Sie ein Antidepressivum aus der Stoffgruppe der MAO-Hemmer (Monoaminoxidase-

Hemmer) einnehmen,

wenn Sie an schweren Leberfunktionsstörungen leiden.

Bei Kindern unter 6 Jahren.

Warnhinweise und Vorsichtsmaßnahmen

Bitte sprechen Sie mit Ihrem Arzt oder Apotheker, bevor Sie Actifed New einnehmen.

Überschreiten Sie weder die empfohlene Höchstdosis noch die Dosierungsfrequenz und halten Sie

die durch den Arzt verordnete Dosierung ein.

Wenden Sie Actifed New nur an, wenn dies notwendig ist.

Sie dürfen Actifed New nicht gleichzeitig mit anderen Arzneimitteln gegen Husten und

Erkältungen anwenden.

Beschränken Sie die Behandlungsdauer auf 5 Tage.

Informieren Sie Ihren Arzt, wenn der Husten länger als 4 bis 5 Tage anhält oder wenn der Husten in

= v25 + GDS1-2-4 + translation correction

Version 26

Verbindung mit Fieber, Hautausschlag oder anhaltenden Kopfschmerzen auftritt.

Informieren Sie Ihren Arzt auch,

wenn Sie Husten in Verbindung mit Asthma, Emphysem oder übermäßigem Auswurf haben;

wenn Sie an einer Leber- und/oder Niereninsuffizienz leiden;

wenn Sie in der Vergangenheit Drogen oder andere Substanzen missbraucht haben;

wenn Sie besondere metabolische Eigenschaften haben, wenn Sie beispielsweise ein

schlechter Metabolisierer von CYP2D6 sind.

Bitte wenden Sie sich an Ihren Arzt, wenn einer der oben genannten Warnhinweise auf Sie zutrifft

oder früher auf Sie zugetroffen hat.

Kinder

Dieses Arzneimittel darf bei Kindern unter 6 Jahren nicht angewendet werden.

Einnahme von Actifed New zusammen mit anderen Arzneimitteln

Informieren Sie Ihren Arzt oder Apotheker wenn Sie andere Arzneimittel einnehmen, kürzlich andere

Arzneimittel eingenommen haben oder beabsichtigen andere Arzneimittel einzunehmen.

Sie dürfen Actifed New nicht gleichzeitig mit anderen Arzneimitteln gegen Husten und Erkältungen

einnehmen.

Sie dürfen Actifed New nicht einnehmen, wenn Sie mit Antidepressiva aus der Gruppe der MAO-

Hemmer (Monoaminooxidase-Hemmer) behandelt werden, auch nicht in den 2 Wochen nach

Einstellung der Behandlung mit diesen MAO-Hemmern.

Informieren Sie Ihren Arzt, wenn Sie Folgendes einnehmen:

Antidepressiva wie selektive Serotoninwiederaufnahme-Hemmer (SSRI),

Bupropion (Antidepressivum und auch zur Rauchstopp-Begleitung),

trizyklische Antidepressiva,

Antipsychotika wie Haloperidol, Perphenazin, Thioridazin,

Arzneimittel, die das Zentralnervensystem unterdrücken, wie beispielsweise opioide

Analgetika wie Methadon; Arzneimittel, die den Schlaf fördern oder Angst abbauen,

Arzneimittel zur Behandlung von Herzrhythmusstörungen wie Chinidin, Amiodaron,

Flecainid, Propafenon,

Terbinafin (ein Arzneimittel zur Behandlung von Pilzinfektionen),

Cinacalcet (ein Arzneimittel zur Kontrolle des Parathormonspiegels).

Wenn Sie eines der oben genannten Arzneimittel einnehmen, wird Ihr Arzt möglicherweise

beschließen, Ihre Behandlung mit Actifed New zu beenden oder die Dosis zu senken.

Einnahme von Actifed New zusammen mit Nahrungsmitteln, Getränken und Alkohol

Vermeiden Sie während der Behandlung den Konsum von Alkohol.

Schwangerschaft, Stillzeit

und Fortpflanzungsfähigkeit

Wenn Sie schwanger sind oder stillen, oder wenn Sie vermuten, schwanger zu sein oder beabsichtigen,

schwanger zu werden, fragen Sie vor der Einnahme dieses Arzneimittels Ihren Arzt oder Apotheker

um Rat.

Sie dürfen Actifed New Sirup während der Schwangerschaft oder Stillzeit nicht einnehmen.

Zu den Auswirkungen von Actifed New auf die Fortpflanzungsfähigkeit bei Männern und Frauen

liegen keine Angaben vor.

Verkehrstüchtigkeit und Fähigkeit zum Bedienen von Maschinen

Bei bestimmten sehr empfindlichen Personen oder bei übermäßiger Anwendung kann Actifed New

Schläfrigkeit und Schwindel hervorrufen. Beim Führen von Fahrzeugen oder beim Bedienen von

= v25 + GDS1-2-4 + translation correction

Version 26

Maschinen ist besondere Vorsicht geboten.

Die Kombination mit Alkohol oder Beruhigungsmitteln erhöht das Risiko auf Schläfrigkeit weiter.

Actifed New enthält Sorbitol, Parabene, den Farbstoff Gelborange S und Ethanol

Dieses Arzneimittel enthält etwa 3 g Sorbitol (E 420) pro 5 ml Sirup. Sorbitol kann Magen-Darm-

Beschwerden verursachen und eine leicht abführende Wirkung haben. Sorbitol ist eine Fructosequelle.

Wenn Ihnen Ihr Arzt gesagt hat, dass Sie (oder Ihr Kind) bestimmte Zuckerarten nicht vertragen oder

wenn bei Ihnen eine angeborene Fructoseintoleranz diagnostiziert wurde, eine seltene genetische

Störung, gekennzeichnet durch die Unfähigkeit, Fructose abzubauen, sprechen Sie darüber mit Ihrem

Arzt, bevor Sie (oder Ihr Kind) dieses Arzneimittel einnehmen oder erhalten.

Dieses Arzneimittel enthält Parabene (E218 und E216). Diese können allergische Reaktionen, auch

Spätreaktionen, hervorrufen.

Dieses Arzneimittel enthält den Farbstoff Gelborange S (E110). Dieser kann allergische Reaktionen

hervorrufen.

Dieses Arzneimittel enthält geringe Mengen an Ethanol (Alkohol), weniger als 100mg pro 5 ml Sirup.

3. Wie ist Actifed New einzunehmen?

Nehmen Sie dieses Arzneimittel immer genau nach Absprache mit Ihrem Arzt ein. Fragen Sie bei

Ihrem Arzt oder Apotheker nach, wenn Sie sich nicht sicher sind.

Dieses Arzneimittel ist nur zum Einnehmen über den Mund bestimmt.

Sie dürfen die angegebene Dosis oder die Anzahl der Einnahmen pro Tag nicht überschreiten.

Ein Teelöffel (5 ml) Actifed New enthält 15 mg Dextromethorphanhydrobromid.

Erwachsene und Kinder über 12 Jahre

30 mg pro Einnahme, also 2 Teelöffel (10 ml), 3- bis 4-mal täglich, je nach Bedarf.

Die Tageshöchstdosis beträgt 120 mg pro 24 Stunden, also 8 Teelöffel.

Anwendung bei Kindern

Kinder zwischen 6 Jahren und 12 Jahren

15 mg pro Einnahme, also 1 Teelöffel (5 ml), 3- bis 4-mal täglich, je nach Bedarf.

Die Tageshöchstdosis beträgt 60 mg pro 24 Stunden, also 4 Teelöffel.

Dieses Arzneimittel darf bei Kindern unter 6 Jahren nicht angewendet werden.

Bitte sprechen Sie mit Ihrem Arzt oder Apotheker, wenn Sie den Eindruck haben, dass die Wirkung

von Actifed New zu stark oder zu schwach ist.

Behandlungsdauer

Die Behandlung ist einzustellen, wenn die Symptome verschwunden sind. Beschränken Sie die

Behandlungsdauer auf 5 Tage (siehe Abschnitt 2).

Wenn Sie eine größere Menge von Actifed New eingenommen haben, als Sie sollten

Es können folgende Beschwerden auftreten:

Übelkeit, Erbrechen,

Erregung, Verwirrtheit,

Schläfrigkeit,

in Ausnahmefällen Krampfanfälle und Atemdepression (Verringerung oder Stillstand der

Atmung).

Wenn Sie zu viel Actifed New eingenommen haben, setzen Sie sich umgehend mit Ihrem Arzt, Ihrem

= v25 + GDS1-2-4 + translation correction

Version 26

Apotheker oder dem „Antigifcentrum“ (070/245.245) in Verbindung oder gehen Sie zu einer

Notaufnahme, um dort behandelt zu werden.

Wenn Sie die Einnahme von Actifed New vergessen haben

Nehmen Sie nicht die doppelte Menge ein, wenn Sie die vorherige Einnahme vergessen haben.

Wenn Sie die Einnahme von Actifed New abbrechen

Wenden Sie sich immer an Ihren Arzt, wenn Sie die Behandlung abbrechen möchten.

Wenn Sie weitere Fragen zur Einnahme dieses Arzneimittels haben, wenden Sie sich an Ihren Arzt

oder Apotheker.

4. Welche Nebenwirkungen sind möglich?

Wie alle Arzneimittel kann auch dieses Arzneimittel Nebenwirkungen haben, die aber nicht bei jedem

auftreten müssen.

Gelegentliche Nebenwirkungen, können bis zu 1 von 100 Personen betreffen:

Übelkeit, Erbrechen, Bauchschmerzen, Magen-Darm-Störungen,

Schwindel, Schläfrigkeit.

Weitere Nebenwirkungen

Weitere Nebenwirkungen wurden bei einer sehr geringen Anzahl von Personen beobachtet, ihre

genaue Häufigkeit ist jedoch nicht bekannt.

Sehstörungen (bei höheren Dosen), in sehr seltenen Fällen und bei der gleichzeitigen

Verabreichung mit Antidepressiva aus der Gruppe der MAO-Hemmer: geistige Verwirrtheit,

Agitiertheit, Schwitzen, Zittern, Schüttelfrost, Hypertonie,

Mydriasis (Erweiterung der Pupille),

allergische Reaktionen wie Angioödem (vorwiegend Schwellung von Gesicht und Rachen) und

Bronchospasmus (Atembeschwerden),

Hautausschläge, Juckreiz, Urtikaria (rote Flecken auf der Haut, die jucken).

Brechen Sie die Einnahme dieses Arzneimittels ab und wenden Sie sich sofort an Ihren Arzt,

wenn Sie eine der folgenden Wirkungen feststellen:

Allergische Reaktionen wie Hautausschläge oder Juckreiz, manchmal in Verbindung mit

Atemproblemen oder einer Schwellung von Lippen, Zunge, Rachen oder Gesicht.

Einige oder alle der folgenden Symptome: Verwirrtheit, Agitiertheit, übermäßiges Schwitzen,

Zittern, Schüttelfrost, plötzliche Muskelzuckungen oder Anstieg des arteriellen Blutdrucks. Es

kann sich um Symptome einer Erkrankung handeln, die unter dem Namen Serotoninsyndrom

bekannt ist.

Meldung von Nebenwirkungen

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies gilt auch

für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind. Sie können

Nebenwirkungen auch direkt über das nationale Meldesystem anzeigen:

Belgien

Föderalagentur für Arzneimittel und

Gesundheitsprodukte

Abteilung Vigilanz

EUROSTATION II

Victor Hortaplein, 40/40

B-1060 BRÜSSEL

Website: www.fagg-afmps.be

E-Mail: patientinfo@fagg-afmps.be

Luxemburg

Direction de la Santé – Division de la Pharmacie et

des Médicaments

Villa Louvigny – Allée Marconi

L-2120 Luxemburg

Website:

http://www.ms.public.lu/fr/activites/pharmacie-

medicament/index.html

= v25 + GDS1-2-4 + translation correction

Version 26

Indem Sie Nebenwirkungen melden, können Sie dazu beitragen, dass mehr Informationen über die

Sicherheit dieses Arzneimittels zur Verfügung gestellt werden.

5. Wie ist Actifed New aufzubewahren?

Bewahren Sie dieses Arzneimittel für Kinder unzugänglich auf.

Sie dürfen dieses Arzneimittel nach dem auf dem Umkarton nach „EXP“ angegebenen Verfalldatum

nicht mehr verwenden. Das Verfalldatum bezieht sich auf den letzten Tag des angegebenen Monats.

Für dieses Arzneimittel sind keine besonderen Lagerungsbedingungen erforderlich.

Entsorgen Sie Arzneimittel nicht im Abwasser oder Haushaltsabfall. Fragen Sie Ihren Apotheker, wie

das Arzneimittel zu entsorgen ist, wenn Sie es nicht mehr verwenden. Sie tragen damit zum Schutz der

Umwelt bei.

6. Inhalt der Packung und weitere Informationen

Was Actifed New enthält

Der Wirkstoff ist Dextromethorphanhydrobromid (15 mg/ 5 ml).

Die sonstigen Bestandteile sind: Methylparahydroxybenzoat (E218) - Propylparahydroxybenzoat

(E216) - Vanillin - Farbstoff Gelborange S (E110) - lösliche, Orangenessenz süß (enthält Ethanol) -

gereinigtes Wasser - Glycerol - nicht kristallisierende Sorbitol-Lösung (E420). Siehe Abschnitt 2 für

einige Bestandteile mit bekannten Wirkungen.

Wie Actifed New aussieht und Inhalt der Packung

Dieses Arzneimittel ist ein Sirup zum Einnehmen in einer braunen Glasflasche zu 180 ml mit

kindersicherem Verschluss.

Pharmazeutischer Unternehmer und Hersteller

Pharmazeutischer Unternehmer

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Site Apollo,

Avenue Pascal, 2-4-6

B-1300 Wavre

Hersteller

Farmaclair

440, avenue du Général de Gaulle

F-14200 Hérouville-Saint-Clair

Frankreich

Art der Abgabe

Verschreibungspflichtig.

= v25 + GDS1-2-4 + translation correction

Version 26

Zulassungsnummer

BE227893

Diese Packungsbeilage wurde zuletzt überarbeitet im

Das Zulassungsdatum: 02/2018

Falls Sie weitere Informationen über das Arzneimittel wünschen, setzen Sie sich bitte mit dem

örtlichen Vertreter des pharmazeutischen Unternehmers in Verbindung.

Belgien/Luxemburg

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Tel: + 32 (0)10 85 52 00

= v25 + GDS1-2-4 + translation correction

15-12-2018

Annual Report of the Scientific Network on BSE‐TSE 2018

Annual Report of the Scientific Network on BSE‐TSE 2018

Published on: Fri, 14 Dec 2018 The EFSA Scientific Network on bovine spongiform encephalopathies and other transmissible spongiform encephalopathies (BSE‐TSE) held its 13th meeting on 15‐16 October 2018 in Parma. The meeting served as an opportunity to exchange scientific information on BSE‐TSE related issues among EU Member States, countries from the European Free Trade Association (EFTA), EFSA, the European Commission and ad hocparticipants. In this occasion, ad hoc representation included the World A...

Europe - EFSA - European Food Safety Authority Publications

14-12-2018

The IMA over Christmas and New Year

The IMA over Christmas and New Year

Opening hours at the Icelandic Medicines Agency during Christmas and New Year

IMA - Icelandic Medicines Agency

14-12-2018

Statement on the safety of d‐ribose

Statement on the safety of d‐ribose

Published on: Thu, 13 Dec 2018 In 2018, the EFSA NDA Panel adopted the Scientific Opinion on the safety of d‐ribose as a novel food pursuant to Regulation (EU) 2015/2283 when used in a variety of food, concluding that d‐ribose is safe for the general population at intake levels up to 36 mg/kg body weight (bw) per day, but that its safety at the intended uses and use levels as proposed by the applicant could not be established. Following a request from the European Commission, the EFSA NDA Panel was aske...

Europe - EFSA - European Food Safety Authority Publications

13-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce E. coli O157:H7 outbreak investigation

FDA - U.S. Food and Drug Administration

11-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency’s biosimilars policy framework

Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency’s biosimilars policy framework

FDA announces new actions advancing the agency’s biosimilars policy framework

FDA - U.S. Food and Drug Administration

10-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new efforts to assure the quality of compounded drugs

Statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new efforts to assure the quality of compounded drugs

FDA releases guidance with recommendations for protecting patients from the risk of contaminated or substandard compounded products produced by outsourcing facilities.

FDA - U.S. Food and Drug Administration

6-12-2018

King Soopers and City Market Recalls Abound Chicken and Brown Rice Dog Food Because of Elevated Vitamin D Levels

King Soopers and City Market Recalls Abound Chicken and Brown Rice Dog Food Because of Elevated Vitamin D Levels

Following a recall by Sunshine Mills, Inc., King Soopers announced it has removed from sale Abound Chicken & Brown Rice Recipe dog food produced by Sunshine Mills, Inc. sold in King Soopers and City Market stores, located in Colorado, Utah, New Mexico and Wyoming. Only Abound Chicken & Brown Rice Recipe dog food with the listed UPC numbers and Best by Dates are affected by this recall. The recall was initiated because the product had the potential to contain an elevated level of Vitamin D, which may caus...

FDA - U.S. Food and Drug Administration

6-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics

FDA releases new strategic framework to advance use of real-world evidence to support development of drugs and biologics

FDA - U.S. Food and Drug Administration

6-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of vitro companion diagnostics for classes of oncology therapeutic products

FDA - U.S. Food and Drug Administration

6-12-2018

Country Flavor Inc Issues Alert on Undeclared Sulfites In "Best Taste Brand Dried Bamboo Shoot"

Country Flavor Inc Issues Alert on Undeclared Sulfites In "Best Taste Brand Dried Bamboo Shoot"

Country Favor Inc. of Maspeth, New York is recalling its 12 ounce packages of "Best Taste Brand DRIED BAMBOO SHOOT" food treats because they contained undeclared sulfites. Consumers who have severe sensitivity to sulfites run the risk of serious or life-threatening allergic reactions if they consume this product.

FDA - U.S. Food and Drug Administration

6-12-2018

Application deadlines in 2018

Application deadlines in 2018

The Danish Medicines Agency will be closed between Christmas and New Year from 22 December 2018 to 1 January 2019, both days inclusive. This means that enquiries made to the Danish Medicines Agency, with a few exceptions, will not be read and replied during this period. On this page, you can find the deadlines that apply to applications in the Danish Medicines Agency's area in 2018.

Danish Medicines Agency

5-12-2018

Pesticides: new deadline for cumulative risk assessments

Pesticides: new deadline for cumulative risk assessments

Pesticides: new deadline for cumulative risk assessments

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

4-12-2018

FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care

FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care

FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care

FDA - U.S. Food and Drug Administration

30-11-2018

FDA authorizes first test to aid in detecting a type of herpes virus in newborns called cytomegalovirus

FDA authorizes first test to aid in detecting a type of herpes virus in newborns called cytomegalovirus

FDA authorizes first test to aid in detecting a type of herpes virus in newborns called cytomegalovirus

FDA - U.S. Food and Drug Administration

29-11-2018

ANSES Newsletter in English - N°50 - November 2018

ANSES Newsletter in English - N°50 - November 2018

France - Agence Nationale du Médicament Vétérinaire

28-11-2018

Sprout Creek Farm Recalls “Kinkead” Cheese due to Possible Health Risk

Sprout Creek Farm Recalls “Kinkead” Cheese due to Possible Health Risk

Sprout Creek Farm of Poughkeepsie, New York is recalling 4 wheels of “Kinkead” cheese made on 5-10-18, because it has the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, L...

FDA - U.S. Food and Drug Administration

28-11-2018

EFSA Scientific Colloquium 24 – 'omics in risk assessment: state of the art and next steps

EFSA Scientific Colloquium 24 – 'omics in risk assessment: state of the art and next steps

Published on: Tue, 27 Nov 2018 In recent years, the development of innovative tools in genomics, transcriptomics, proteomics and metabolomics (designated collectively as 'omics technologies) has opened up new possibilities for applications in scientific research and led to the availability of vast amounts of analytical data. The interpretation and integration of 'omics data can provide valuable information on the functional status of an organism and on the effect of external factors such as stressors. T...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on how modern predicates can promote innovation and advance safety and effectiveness of medical devices that use 510(k) pathway

Statement from FDA Commissioner Scott Gottlieb, M.D., on how modern predicates can promote innovation and advance safety and effectiveness of medical devices that use 510(k) pathway

FDA Commissioner statement on modernizing the 510(k) pathway by creating policies that rely on newer predicates with modern characteristics related to their safety and performance

FDA - U.S. Food and Drug Administration

27-11-2018

Risk assessment of new sequencing information for genetically modified soybean A2704‐12

Risk assessment of new sequencing information for genetically modified soybean A2704‐12

Published on: Mon, 26 Nov 2018 The GMO Panel has previously assessed genetically modified (GM) soybean A2704‐12. This soybean was found to be as safe and nutritious as its conventional counterpart with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 5 June 2018, the European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soybean A2704‐12 and to indicate whether the previous c...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

26-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on transformative new steps to modernize FDA’s 510(k) program to advance the review of the safety and effectiveness of

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on transformative new steps to modernize FDA’s 510(k) program to advance the review of the safety and effectiveness of

FDA provides updates on two elements in medical device safety action plan: modernizing 510(k) program and new process for establishing special controls.

FDA - U.S. Food and Drug Administration

21-11-2018

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment for patients with acute myeloid leukemia

The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

FDA - U.S. Food and Drug Administration

21-11-2018

Implementation and verification of PBPK modelling codes of TCDD in rats and humans into Berkeley Madonna

Implementation and verification of PBPK modelling codes of TCDD in rats and humans into Berkeley Madonna

Published on: Tue, 20 Nov 2018 The goal of the current work was to implement and verify previously published rat and human PBPK modelling codes for TCDD into Berkeley Madonna. The US‐EPA has used these PBPK models in the reassessment of TCDD. A procurement contract has been set up to explore the possibilities to adequately run the models and reproduce previously published results. The implementation of the available codes in Berkeley Madonna was carried out at RIKILT‐WUR under the framework agreement wi...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Relevance of new scientific information (Santos‐Vigil et al., 2018*) in relation to the risk assessment of genetically modified crops with Cry1Ac

Relevance of new scientific information (Santos‐Vigil et al., 2018*) in relation to the risk assessment of genetically modified crops with Cry1Ac

Published on: Wed, 14 Nov 2018 Following a request from the European Commission, EFSA assessed the scientific publication by Santos‐Vigil et al. (2018). The outstanding question was whether or not the new scientific information contains elements that could lead the EFSA GMO Panel to reconsider the outcome of its previous risk assessments on genetically modified crops expressing Cry1Ac protein. Santos‐Vigil et al. (2018) investigated the allergenic potential and immunological effects of the Cry1Ac protei...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Modification of the existing maximum residue levels for pyraclostrobin in soyabean

Modification of the existing maximum residue levels for pyraclostrobin in soyabean

Published on: Mon, 19 Nov 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted a request to the competent national authority in France to modify the existing maximum residue level (MRL) for the active substance pyraclostrobin in soyabean. The data submitted in support of the request were found to be sufficient to derive MRL proposals for soyabean. The applicant provided a new validated analytical method to control residues of pyraclostrobin on the commodity u...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Modification of the existing maximum residue levels and setting of import tolerances for pyraclostrobin in various crops

Modification of the existing maximum residue levels and setting of import tolerances for pyraclostrobin in various crops

Published on: Mon, 19 Nov 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted two requests to the competent national authority in Germany. The first one, to modify the existing maximum residue levels (MRL) for the active substance pyraclostrobin in various crops and to set import tolerances for sugar canes and American persimmons; the second one to set import tolerances for pineapples and passion fruits/maracujas. The data submitted in support of the request...

Europe - EFSA - European Food Safety Authority Publications

19-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on a new qualified health claim for consuming oils with high levels of oleic acid to reduce coronary heart disease risk

Statement from FDA Commissioner Scott Gottlieb, M.D., on a new qualified health claim for consuming oils with high levels of oleic acid to reduce coronary heart disease risk

FDA issues a qualified health claim for oleic acid oils based on data showing it reduces cholesterols levels.

FDA - U.S. Food and Drug Administration

17-11-2018

Assessment of genetically modified soybean MON 89788 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐011)

Assessment of genetically modified soybean MON 89788 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐011)

Published on: Fri, 16 Nov 2018 Following the submission of application EFSA‐GMO‐RX‐011 under Regulation (EC) No 1829/2003 from Monsanto Europe, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the herbicide‐tolerant genetically modified soybean MON 89788, for food and feed uses, excluding cultivation within the European Union....

Europe - EFSA - European Food Safety Authority Publications

17-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Published on: Fri, 16 Nov 2018 The applicant BASF Agro B.V. submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for picolinafen in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, a new validated analytical method for enforcement of the residue in dry/high starch‐, high water content‐, high acid content‐ and high oil content commodities ...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

FDA approves new drug to treat travelers’ diarrhea

FDA approves new drug to treat travelers’ diarrhea

FDA approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

FDA - U.S. Food and Drug Administration

16-11-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs

The FDA is committed to making sure post-market studies are transparent to the public and that industry is fulfilling their PMRs and PMCs.

FDA - U.S. Food and Drug Administration

16-11-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce animal testing through a study aimed at eliminating the use of dogs in certain trials

Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce animal testing through a study aimed at eliminating the use of dogs in certain trials

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to reduce use of animals through a study aimed at eliminating the use of dogs in certain trials

FDA - U.S. Food and Drug Administration

16-11-2018

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.

FDA - U.S. Food and Drug Administration

16-11-2018

Setting of an import tolerance for pyraclostrobin in rice

Setting of an import tolerance for pyraclostrobin in rice

Published on: Thu, 15 Nov 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted a request to the competent national authority in Germany to set an import tolerance for the active substance pyraclostrobin in rice. The data submitted in support of the request were found to be sufficient to derive a maximum residue level (MRL) proposal for rice. Based on the risk assessment results, EFSA concluded that the short‐term intake of residues resulting from the use of p...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Published on: Thu, 15 Nov 2018 The applicant BASF SE submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for pyraclostrobin in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, residues trials supporting the existing use of pyraclostrobin on table grapes authorised in southern EU Member States and an analytical method for analysing residues of pyraclostrobin in ...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year

Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year

New findings from the National Youth Tobacco Survey show that more than 3.6 million middle and high school students were current (past 30 day) e-cigarette users in 2018.

FDA - U.S. Food and Drug Administration

15-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes

FDA - U.S. Food and Drug Administration

15-11-2018

Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐010)

Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐010)

Published on: Wed, 14 Nov 2018 Following the submission of application EFSA‐GMO‐RX‐010 under Regulation (EC) No 1829/2003 from Bayer, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the herbicide‐tolerant genetically modified LLCotton25, for food and feed uses, import and processing, excluding cultivation within the EU. The d...

Europe - EFSA - European Food Safety Authority Publications

14-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for cyazofamid

Evaluation of confirmatory data following the Article 12 MRL review for cyazofamid

Published on: Tue, 13 Nov 2018 The applicant ISK Biosciences Europe N.V. submitted a request to the competent national authority in France to evaluate the confirmatory data that were identified in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. The data gap which was related to information on freezer storage conditions for the residue trials reported on potatoes, tomatoes and cucurbits with edible and inedible peel was considered satisfactorily addressed...

Europe - EFSA - European Food Safety Authority Publications

10-11-2018

Pest categorisation of Popillia japonica

Pest categorisation of Popillia japonica

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Popillia japonica(Coleoptera: Scarabaeidae) for the EU. P. japonica is a distinguishable species listed in Annex IAII of Council Directive 2000/29/EC. It is native to Japan but established in the USA in the early 20th century. It spreads from New Jersey to most US states east of the Mississippi, some to the west and north into Canada. P. japonica feeds on over 700 plant species. Adults attack folia...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs

FDA is taking steps to modernize the agency’s inspections program

FDA - U.S. Food and Drug Administration

8-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

The FDA is committed to the expanded access program which provides a pathway for patients to gain access to investigational drugs, biologics and medical devices for serious diseases and life-threatening conditions outside of clinical trials when no comparable or satisfactory approved alternative therapy options are available.

FDA - U.S. Food and Drug Administration

14-12-2018

#ICYMI: @SGottliebFDA issued a statement on the #FDA’s new effort for  developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products. Read the statement here:  https://go.usa.gov/xE3kk  #MedicalDevice

#ICYMI: @SGottliebFDA issued a statement on the #FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products. Read the statement here: https://go.usa.gov/xE3kk  #MedicalDevice

#ICYMI: @SGottliebFDA issued a statement on the #FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products. Read the statement here: https://go.usa.gov/xE3kk  #MedicalDevice

FDA - U.S. Food and Drug Administration

5-12-2018

Updates to the Database of TGA laboratory testing results

Updates to the Database of TGA laboratory testing results

New release of results published

Therapeutic Goods Administration - Australia

29-11-2018

TGA presentation: Advertising Therapeutic Goods to consumers - Complaints handling

TGA presentation: Advertising Therapeutic Goods to consumers - Complaints handling

An overview of the TGA's new advertising complaints handling framework.

Therapeutic Goods Administration - Australia

27-11-2018

Reclassification of surgical mesh medical devices

Reclassification of surgical mesh medical devices

New guidance to assist sponsors with the reclassification of surgical mesh devices

Therapeutic Goods Administration - Australia

26-11-2018

It would also help make sure that newer devices reflect more modern technologies and standards that can improve patient care and outcomes. It would help the overall product environment continue to evolve in the direction toward safer, more effective devic

It would also help make sure that newer devices reflect more modern technologies and standards that can improve patient care and outcomes. It would help the overall product environment continue to evolve in the direction toward safer, more effective devic

It would also help make sure that newer devices reflect more modern technologies and standards that can improve patient care and outcomes. It would help the overall product environment continue to evolve in the direction toward safer, more effective devices.

FDA - U.S. Food and Drug Administration

26-11-2018

We believe that encouraging product developers to use more modern predicates would give patients and their doctors a choice among older and newer versions of a type of device while promoting greater competition to adopt modern features that improve safety

We believe that encouraging product developers to use more modern predicates would give patients and their doctors a choice among older and newer versions of a type of device while promoting greater competition to adopt modern features that improve safety

We believe that encouraging product developers to use more modern predicates would give patients and their doctors a choice among older and newer versions of a type of device while promoting greater competition to adopt modern features that improve safety and performance.

FDA - U.S. Food and Drug Administration

26-11-2018

These examples help illustrate why we believe that newer devices should be compared to the benefits and risks of more modern technologies and why we’re looking at ways to promote the use of more recent predicates

These examples help illustrate why we believe that newer devices should be compared to the benefits and risks of more modern technologies and why we’re looking at ways to promote the use of more recent predicates

These examples help illustrate why we believe that newer devices should be compared to the benefits and risks of more modern technologies and why we’re looking at ways to promote the use of more recent predicates

FDA - U.S. Food and Drug Administration

26-11-2018

An infusion pump whose predicate device uses older “beam break” technology to estimate the size of the drop.  The new device uses a video camera and vision processing to monitor the drop formation and detect drops falling, making the device more precise a

An infusion pump whose predicate device uses older “beam break” technology to estimate the size of the drop. The new device uses a video camera and vision processing to monitor the drop formation and detect drops falling, making the device more precise a

An infusion pump whose predicate device uses older “beam break” technology to estimate the size of the drop. The new device uses a video camera and vision processing to monitor the drop formation and detect drops falling, making the device more precise and more accurate.

FDA - U.S. Food and Drug Administration

26-11-2018

An X-ray system that includes a controller to control time of x-ray exposure. These new devices now meet performance standards and consensus standards that were either not available or have been revised to meet more modern criteria since the predicate dev

An X-ray system that includes a controller to control time of x-ray exposure. These new devices now meet performance standards and consensus standards that were either not available or have been revised to meet more modern criteria since the predicate dev

An X-ray system that includes a controller to control time of x-ray exposure. These new devices now meet performance standards and consensus standards that were either not available or have been revised to meet more modern criteria since the predicate device was cleared

FDA - U.S. Food and Drug Administration

26-11-2018

In 510(k), manufacturers often rely on comparative testing vs predicate devices to show a new device is as safe and effective as the predicate. But older predicates might not closely reflect the modern tech embedded in new devices or more current understa

In 510(k), manufacturers often rely on comparative testing vs predicate devices to show a new device is as safe and effective as the predicate. But older predicates might not closely reflect the modern tech embedded in new devices or more current understa

In 510(k), manufacturers often rely on comparative testing vs predicate devices to show a new device is as safe and effective as the predicate. But older predicates might not closely reflect the modern tech embedded in new devices or more current understanding of benefits & risks

FDA - U.S. Food and Drug Administration

26-11-2018

We believe in merits of 510(k) process, but also believe it must be modernized to reflect advances in technology, safety, capabilities of newer devices. It’s time to fundamentally modernize an approach first adopted in 1976 c/w Medical Device Safety Actio

We believe in merits of 510(k) process, but also believe it must be modernized to reflect advances in technology, safety, capabilities of newer devices. It’s time to fundamentally modernize an approach first adopted in 1976 c/w Medical Device Safety Actio

We believe in merits of 510(k) process, but also believe it must be modernized to reflect advances in technology, safety, capabilities of newer devices. It’s time to fundamentally modernize an approach first adopted in 1976 c/w Medical Device Safety Action we issued in April 2018

FDA - U.S. Food and Drug Administration

26-11-2018

As device technology evolves and becomes increasingly complex, #FDA needs to keep pace. Our proposed changes to the 510(k) clearance pathway will allow FDA to retire outdated predicates and use new technologies to promote innovation and improved safety.

As device technology evolves and becomes increasingly complex, #FDA needs to keep pace. Our proposed changes to the 510(k) clearance pathway will allow FDA to retire outdated predicates and use new technologies to promote innovation and improved safety.

As device technology evolves and becomes increasingly complex, #FDA needs to keep pace. Our proposed changes to the 510(k) clearance pathway will allow FDA to retire outdated predicates and use new technologies to promote innovation and improved safety. https://go.usa.gov/xPHdE 

FDA - U.S. Food and Drug Administration

26-11-2018

Mirvaso (Galderma International)

Mirvaso (Galderma International)

Mirvaso (Active substance: brimonidine) - Centralised - Renewal - Commission Decision (2018)7977 of Mon, 26 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2642/R/21

Europe -DG Health and Food Safety

26-11-2018

Ixiaro (Valneva Austria GmbH)

Ixiaro (Valneva Austria GmbH)

Ixiaro (Active substance: Japanese Encephalitis vaccine (inactivated, adsorbed)) - Centralised - Renewal - Commission Decision (2018)7979 of Mon, 26 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/963/R/91

Europe -DG Health and Food Safety

22-11-2018

Brintellix (H. Lundbeck A/S)

Brintellix (H. Lundbeck A/S)

Brintellix (Active substance: vortioxetine) - Centralised - Renewal - Commission Decision (2018)7896 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2717/R/19

Europe -DG Health and Food Safety

22-11-2018

Levetiracetam Hospira (Hospira UK Limited)

Levetiracetam Hospira (Hospira UK Limited)

Levetiracetam Hospira (Active substance: levetiracetam) - Centralised - Renewal - Commission Decision (2018)7895 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2783/R/18

Europe -DG Health and Food Safety

22-11-2018

Neuraceq (Life Radiopharma Berlin GmbH)

Neuraceq (Life Radiopharma Berlin GmbH)

Neuraceq (Active substance: florbetaben (18F)) - Centralised - Renewal - Commission Decision (2018)7882 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2553/R/25

Europe -DG Health and Food Safety

21-11-2018

Guidance on the regulation of menstrual cups in Australia

Guidance on the regulation of menstrual cups in Australia

New guidance for menstrual cups published

Therapeutic Goods Administration - Australia

20-11-2018

#FDA has set important new goal when it comes to device safety: ensuring that we’re consistently first in the world to identify and act upon device safety signals to protect patients.  https://go.usa.gov/xPAf7 pic.twitter.com/IATHeEUgHe

#FDA has set important new goal when it comes to device safety: ensuring that we’re consistently first in the world to identify and act upon device safety signals to protect patients. https://go.usa.gov/xPAf7 pic.twitter.com/IATHeEUgHe

#FDA has set important new goal when it comes to device safety: ensuring that we’re consistently first in the world to identify and act upon device safety signals to protect patients. https://go.usa.gov/xPAf7  pic.twitter.com/IATHeEUgHe

FDA - U.S. Food and Drug Administration

16-11-2018

Latuda (Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.)

Latuda (Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.)

Latuda (Active substance: lurasidone) - Centralised - Renewal - Commission Decision (2018)7674 of Fri, 16 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2713/R/20

Europe -DG Health and Food Safety